Imbalance of the vanin-1 pathway in systemic sclerosis

Journal of Immunology

Volumn 197, Issue 8, 2016, Pages 3326-3335

  Kavian, Niloufar ^a   Mehlal, Souad ^a   Marut, Wioleta ^a   Servettaz, Amelie ^b   Giessner, Caroline ^c   Bourges, Christophe ^c   Nicco, Carole ^a   Chéreau, Christiane ^a   Lemaréchal, Herve ^d   Dutilh, Marie Flore ^a   Cerles, Olivier ^a   Guilpain, Philippe ^e   Vuiblet, Vincent ^b   Chouzenoux, Sandrine ^a   Galland, Franck ^c   Quere, Isabelle ^f   Weill, Bernard ^a   Naquet, Philippe ^c   Batteux, Frédéric ^a  

^a INSTITUT COCHIN   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIV MONTPELLIER   (France)

^f HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHLOROUS ACID; PANTOTHENIC ACID; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VANIN 1; AMIDASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PANTETHEINASE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEFECT; ENZYME INACTIVATION; ENZYME LOCALIZATION; ENZYME REGULATION; FEMALE; GENE INACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANTOTHENIC ACID BLOOD LEVEL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VITAMIN BLOOD LEVEL; VNN1 GENE; ANIMAL; BAGG ALBINO MOUSE; METABOLISM;

AMIDOHYDROLASES; ANIMALS; FEMALE; GPI-LINKED PROTEINS; MICE; MICE, INBRED BALB C; PANTOTHENIC ACID; SCLERODERMA, SYSTEMIC;

EID: 84991516812     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502511     Document Type: Article

References (45)

1. Gabrielli, A., E. V. Avvedimento, and T. Krieg. 2009. Scleroderma. N. Engl. J. Med. 360: 1989-2003.
2. Harris, M. L., and A. Rosen. 2003. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr. Opin. Rheumatol. 15: 778-784.
3. Servettaz, A., C. Goulvestre, N. Kavian, C. Nicco, P. Guilpain, C. Chéreau, V. Vuiblet, L. Guillevin, L. Mouthon, B. Weill, and F. Batteux. 2009. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J. Immunol. 182: 5855-5864.
4. Baroni, S. S., M. Santillo, F. Bevilacqua, M. Luchetti, T. Spadoni, M. Mancini, P. Fraticelli, P. Sambo, A. Funaro, A. Kazlauskas, et al. 2006. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med. 354: 2667-2676.
5. Servettaz, A., P. Guilpain, C. Goulvestre, C. Chéreau, C. Hercend, C. Nicco, L. Guillevin, B. Weill, L. Mouthon, and F. Batteux. 2007. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann. Rheum. Dis. 66: 1202-1209.
6. Kavian, N., W. Marut, A. Servettaz, C. Nicco, C. Chéreau, H. Lemaréchal, D. Borderie, N. Dupin, B. Weill, and F. Batteux. 2012. Reactive oxygen speciesmediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosis. Arthritis Rheum. 64: 3430-3440.
7. Maras, B., D. Barra, S. Duprè, and G. Pitari. 1999. Is pantetheinase the actual identity of mouse and human vanin-1 proteins? FEBS Lett. 461: 149-152.
8. Martin, F., F. Malergue, G. Pitari, J. M. Philippe, S. Philips, C. Chabret, S. Granjeaud, M. G. Mattei, A. J. Mungall, P. Naquet, and F. Galland. 2001. Vanin genes are clustered (human 6q22-24 and mouse 10A2B1) and encode isoforms of pantetheinase ectoenzymes. Immunogenetics 53: 296-306.
9. Naquet, P., G. Pitari, S. Duprè, and F. Galland. 2014. Role of the Vnn1 pantetheinase in tissue tolerance to stress. Biochem. Soc. Trans. 42: 1094-1100.
10. Duprè, S., and D. Cavallini. 1979. Purification and properties of pantetheinase from horse kidney. Methods Enzymol. 62: 262-267.
11. Penet, M. F., M. Abou-Hamdan, N. Coltel, E. Cornille, G. E. Grau, M. de Reggi, and B. Gharib. 2008. Protection against cerebral malaria by the low-molecularweight thiol pantethine. Proc. Natl. Acad. Sci. USA 105: 1321-1326.
12. Gaddi, A., G. C. Descovich, G. Noseda, C. Fragiacomo, L. Colombo, A. Craveri, G. Montanari, and C. R. Sirtori. 1984. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. Atherosclerosis 50: 73-83.
13. Prisco, D., P. G. Rogasi, M. Matucci, R. Paniccia, R. Abbate, G. F. Gensini, and G. G. Neri Serneri. 1987. Effect of oral treatment with pantethine on platelet and plasma phospholipids in IIa hyperlipoproteinemia. Angiology 38: 241-247.
14. Eto, M., K.Watanabe, N. Chonan, and K. Ishii. 1987. Lowering effect of pantethine on plasma beta-thromboglobulin and lipids in diabetes mellitus. Artery 15: 1-12.
15. Martin, F., M. F. Penet, F. Malergue, H. Lepidi, A. Dessein, F. Galland, M. de Reggi, P. Naquet, and B. Gharib. 2004. Vanin-1(2/2) mice show decreased NSAID-and Schistosoma-induced intestinal inflammation associated with higher glutathione stores. J. Clin. Invest. 113: 591-597.
16. Griffith, O. W., A. Larsson, and A. Meister. 1977. Inhibition of gammaglutamylcysteine synthetase by cystamine: an approach to a therapy of 5-oxoprolinuria (pyroglutamic aciduria). Biochem. Biophys. Res. Commun. 79: 919-925.
17. Combes, V., N. Coltel, D. Faille, S. C. Wassmer, and G. E. Grau. 2006. Cerebral malaria: role of microparticles and platelets in alterations of the blood-brain barrier. Int. J. Parasitol. 36: 541-546.
18. Weimann, B. I., and D. Hermann. 1999. Studies on wound healing: effects of calcium D-pantothenate on the migration, proliferation and protein synthesis of human dermal fibroblasts in culture. Int. J. Vitam. Nutr. Res. 69:113-119.
19. Kobayashi, D., M. Kusama, M. Onda, and N. Nakahata. 2011. The effect of pantothenic acid deficiency on keratinocyte proliferation and the synthesis of keratinocyte growth factor and collagen in fibroblasts. J. Pharmacol. Sci. 115: 230-234.
20. Jansen, P. A., M. Kamsteeg, D. Rodijk-Olthuis, I. M. van Vlijmen-Willems, G. J. de Jongh, M. Bergers, G. S. Tjabringa, P. L. Zeeuwen, and J. Schalkwijk. 2009. Expression of the vanin gene family in normal and inflamed human skin: induction by proinflammatory cytokines. J. Invest. Dermatol. 129: 2167-2174.
21. Pitari, G., F. Malergue, F. Martin, J. M. Philippe, M. T. Massucci, C. Chabret, B. Maras, S. Duprè, P. Naquet, and F. Galland. 2000. Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 deficient mice. FEBS Lett. 483: 149-154.
22. Meghari, S., C. Berruyer, H. Lepidi, F. Galland, P. Naquet, and J. L. Mege. 2007. Vanin-1 controls granuloma formation and macrophage polarization in Coxiella burnetii infection. Eur. J. Immunol. 37: 24-32.
23. Berruyer, C., L. Pouyet, V. Millet, F. M. Martin, A. LeGoffic, A. Canonici, S. Garcia, C. Bagnis, P. Naquet, and F. Galland. 2006. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J. Exp. Med. 203: 2817-2827.
24. Berruyer, C., F. M. Martin, R. Castellano, A. Macone, F. Malergue, S. Garrido-Urbani, V. Millet, J. Imbert, S. Duprè, G. Pitari, et al. 2004. Vanin-1-/-mice exhibit a glutathione-mediated tissue resistance to oxidative stress. Mol. Cell. Biol. 24: 7214-7224.
25. Rommelaere, S., V. Millet, T. Gensollen, C. Bourges, J. Eeckhoute, N. Hennuyer, E. Baugé, L. Chasson, I. Cacciatore, B. Staels, et al. 2013. PPARalpha regulates the production of serum Vanin-1 by liver. FEBS Lett. 587: 3742-3748.
26. Kurien, B. T., K. Hensley, M. Bachmann, and R. H. Scofield. 2006. Oxidatively modified autoantigens in autoimmune diseases. Free Radic. Biol. Med. 41: 549-556.
27. Griffiths, H. R. 2008. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease? Autoimmun. Rev. 7: 544-549.
28. Iuchi, Y., N. Kibe, S. Tsunoda, S. Suzuki, T. Mikami, F. Okada, K. Uchida, and J. Fujii. 2010. Implication of oxidative stress as a cause of autoimmune hemolytic anemia in NZB mice. Free Radic. Biol. Med. 48: 935-944.
29. Yamamoto, T., S. Takagawa, I. Katayama, K. Yamazaki, Y. Hamazaki, H. Shinkai, and K. Nishioka. 1999. Animal model of sclerotic skin I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J. Invest. Dermatol. 112: 456-462.
30. Woessner Jr., J. F., 1961. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys. 93: 440-447.
31. Marut, W., N. Kavian, A. Servettaz, T. Hua-Huy, C. Nicco, C. Chéreau, B. Weill, A. T. Dinh-Xuan, and F. Batteux. 2013. Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade. Arthritis Rheum. 65: 1367-1377.
32. Kavian, N., A. Servettaz, C. Mongaret, A.Wang, C. Nicco, C. Chéreau, P. Grange, V. Vuiblet, P. Birembaut, M. D. Diebold, et al. 2010. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 62: 3477-3487.
33. LeRoy, E. C., and T. A. Medsger, Jr. 2001. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28: 1573-1576.
34. van den Hoogen, F., D. Khanna, J. Fransen, S. R. Johnson, M. Baron, A. Tyndall, M. Matucci-Cerinic, R. P. Naden, T. A. Medsger, Jr., P. E. Carreira, et al. 2013. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 65: 2737-2747.
35. Gensollen, T., C. Bourges, P. Rihet, A. Rostan, V. Millet, T. Noguchi, V. Bourdon, H. Sobol, L. Dubuquoy, B. Bertin, et al. 2013. Functional polymorphisms in the regulatory regions of the VNN1 gene are associated with susceptibility to inflammatory bowel diseases. Inflamm. Bowel Dis. 19: 2315-2325.
36. Batteux, F., N. Kavian, and A. Servettaz. 2011. New insights on chemically induced animal models of systemic sclerosis. Curr. Opin. Rheumatol. 23: 511-518.
37. Wittwer, C. T., W. A. Gahl, J. D. Butler, M. Zatz, and J. G. Thoene. 1985. Metabolism of pantethine in cystinosis. J. Clin. Invest. 76: 1665-1672.
38. Bouazza, N., J. M. Tréluyer, C. Ottolenghi, S. Urien, G. Deschenes, D. Ricquier, P. Niaudet, and B. Chadefaux-Vekemans. 2011. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients. Orphanet J. Rare Dis. 6: 86.
39. Sambo, P., S. S. Baroni, M. Luchetti, P. Paroncini, S. Dusi, G. Orlandini, and A. Gabrielli. 2001. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 44: 2653-2664.
40. Herrick, A. L., and M. Matucci Cerinic. 2001. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin. Exp. Rheumatol. 19: 4-8.
41. Dammanahalli, K. J., S. Stevens, and R. Terkeltaub. 2012. Vanin-1 pantetheinase drives smooth muscle cell activation in post-arterial injury neointimal hyperplasia. PLoS One 7: e39106.
42. Granjeaud, S., P. Naquet, and F. Galland. 1999. An ESTs description of the new Vanin gene family conserved from fly to human. Immunogenetics 49: 964-972.
43. Zhang, B., C. Lo, L. Shen, R. Sood, C. Jones, K. Cusmano-Ozog, S. Park-Snyder, W. Wong, M. Jeng, T. Cowan, et al. 2011. The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP. Blood 117: 4569-4579.
44. Yamamoto, T., S. Takagawa, I. Katayama, Y. Mizushima, and K. Nishioka. 1999. Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: implications for the treatment of systemic sclerosis. J. Invest. Dermatol. 113: 843-847.
45. Silman, A., M. Harrison, and P. Brennan. 1995. Is it possible to reduce observer variability in skin score assessment of scleroderma? The ad hoc International Group on the Assessment of Disease Outcome in Scleroderma. J. Rheumatol. 22: 1277-1280.